SLDB - NASDAQ
Solid Biosciences Inc.
$6.85
+4.1%Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotSolid Biosciences Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Solid Biosciences Inc. Cash Flow Statement
SLDB • NASDAQ
| Solid Biosciences Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||
-174.3M | -124.7M | -96M | -86M | -72.2M | -88.3M | -117.2M | -74.8M | -53.2M | -23.8M | -6.7M | |
-1.9M | 2.5M | 2.6M | 2.4M | 3M | 3.9M | 2.8M | 1.6M | 448K | 56K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 1.2M | 0.0 | 0.0 | 0.0 | 206K | 505K | 0.0 | |
16.9M | 10.5M | 7.6M | 7.5M | 13.4M | 11.6M | 14.2M | 6M | 5.3M | 1.5M | 764K | |
9.8M | 8.9M | -2M | -18.3M | -81K | -20K | -277K | -86K | -459K | -1.2M | 108K | |
-6.8M | 2.9M | -6.3M | -3.7M | -23M | 16.2M | 7.8M | -2.8M | 4.4M | 2.8M | 1.6M | |
-156.3M | -100M | -94.2M | -98M | -77.8M | -56.6M | -92.7M | -70.2M | -43.2M | -20.1M | -4.2M | |
INVESTING ACTIVITIES | |||||||||||
-1.2M | -654K | -1.5M | -3M | -1.3M | -899K | -4.4M | -7.8M | -2.3M | -392K | (0.0) | |
(85K) | (5K) | (0.0) | (31.5M) | (89.8M) | -7.5M | -24.5M | (0.0) | (0.0) | (0.0) | (0.0) | |
-235.9M | -204.3M | -117.4M | -182.8M | -141.2M | -401K | -31.5M | -44.3M | -18.9M | -25.7M | -26.8M | |
178.5M | 188.9M | 128.6M | 212.8M | 51.4M | 7.9M | 60.4M | 25.3M | 31.6M | 22M | 0.0 | |
0.0 | 0.0 | 0.0 | 600K | -89.8M | 7.5M | 24.5M | -19M | 100K | -165K | -26.8M | |
-58.5M | -16.1M | (9.7M) | (59.2M) | -91.1M | (6.6M) | (24.5M) | -26.8M | (10.5M) | -4.2M | -26.8M | |
FINANCING ACTIVITIES | |||||||||||
194.7M | 122.1M | 3M | 72.6M | 134.9M | 132.5M | 49.3M | 133.7M | 0.0 | 0.0 | 0.0 | |
-723K | -473K | 0.0 | 2.1M | 0.0 | 0.0 | 0.0 | -13K | 0.0 | 0.0 | 0.0 | |
(0.0) | -5.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
425K | 794K | 148K | 203K | 107K | 0.0 | 8.6M | -2.2M | -2.4M | 0.0 | 44.8M | |
194.4M | 122.4M | 3.1M | 74.8M | 135M | 128.7M | 57.9M | 131.5M | 77.1M | 3.4M | 51.6M | |
CASH FLOW SUMMARY | |||||||||||
-20.3M | 6.3M | -81.4M | 36M | -33.9M | 78.7M | -10.3M | 34.5M | 44.4M | -20.9M | 20.6M | |
82.2M | 75.8M | 155.4M | 121.2M | 155.1M | 76.4M | 86.7M | 52.1M | 7.7M | 28.6M | 8M | |
61.9M | 82.2M | 74M | 157.2M | 121.2M | 155.1M | 76.4M | 86.7M | 52.1M | 7.7M | 28.6M | |
-157.4M | -100.7M | -95.7M | -101M | -79M | -57.5M | -97.1M | -78M | -45.5M | -20.5M | -4.2M |
SEC Filings
SLDB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 10, 2026 | 2026 | |
S-3 S-3 N/A | March 19, 2026 | March 19, 2026 | ||
S-3 S-3 N/A | March 19, 2026 | March 19, 2026 | ||
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your SLDB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.